Ahmed Sallam
Concepts (391)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Vitrectomy | 31 | 2024 | 59 | 10.280 |
Why?
| Phacoemulsification | 18 | 2025 | 35 | 8.740 |
Why?
| Visual Acuity | 40 | 2025 | 144 | 8.620 |
Why?
| Macular Edema | 18 | 2024 | 30 | 8.420 |
Why?
| Cataract | 14 | 2024 | 45 | 7.350 |
Why?
| Cataract Extraction | 15 | 2024 | 33 | 6.310 |
Why?
| Intraoperative Complications | 17 | 2025 | 114 | 5.720 |
Why?
| Retinal Detachment | 15 | 2024 | 26 | 5.660 |
Why?
| Tomography, Optical Coherence | 21 | 2025 | 107 | 5.050 |
Why?
| Diabetic Retinopathy | 10 | 2024 | 44 | 4.710 |
Why?
| Uveitis | 13 | 2024 | 21 | 4.220 |
Why?
| Postoperative Complications | 18 | 2024 | 1033 | 3.890 |
Why?
| Glaucoma | 9 | 2024 | 35 | 3.780 |
Why?
| Ophthalmology | 8 | 2023 | 32 | 3.780 |
Why?
| Glucocorticoids | 16 | 2024 | 230 | 3.360 |
Why?
| Endophthalmitis | 11 | 2023 | 25 | 3.280 |
Why?
| Lens Implantation, Intraocular | 10 | 2025 | 24 | 3.280 |
Why?
| Epiretinal Membrane | 5 | 2024 | 10 | 3.260 |
Why?
| Retrospective Studies | 56 | 2025 | 6263 | 3.010 |
Why?
| Eye Infections, Bacterial | 8 | 2024 | 29 | 2.840 |
Why?
| Dexamethasone | 9 | 2023 | 432 | 2.690 |
Why?
| Humans | 134 | 2025 | 50503 | 2.580 |
Why?
| Comprehension | 7 | 2024 | 116 | 2.470 |
Why?
| Drug Implants | 9 | 2023 | 35 | 2.460 |
Why?
| Triticum | 4 | 2023 | 7 | 2.440 |
Why?
| Intraocular Pressure | 11 | 2024 | 58 | 2.230 |
Why?
| Fluorescein Angiography | 7 | 2024 | 34 | 2.230 |
Why?
| Syphilis | 5 | 2024 | 27 | 2.230 |
Why?
| Hordeum | 3 | 2022 | 5 | 2.100 |
Why?
| Vitreoretinal Surgery | 5 | 2024 | 8 | 2.090 |
Why?
| Diabetes Mellitus | 4 | 2022 | 279 | 1.980 |
Why?
| Eye Infections, Fungal | 6 | 2021 | 19 | 1.900 |
Why?
| Retinal Vessels | 3 | 2024 | 15 | 1.900 |
Why?
| Retinal Vein Occlusion | 6 | 2023 | 14 | 1.890 |
Why?
| Papilledema | 4 | 2022 | 27 | 1.860 |
Why?
| Retinitis Pigmentosa | 2 | 2024 | 8 | 1.780 |
Why?
| Aged | 44 | 2025 | 9741 | 1.760 |
Why?
| Middle Aged | 47 | 2025 | 12611 | 1.710 |
Why?
| Retinal Diseases | 8 | 2025 | 51 | 1.640 |
Why?
| Eye Diseases | 4 | 2025 | 34 | 1.610 |
Why?
| Aged, 80 and over | 26 | 2025 | 3226 | 1.610 |
Why?
| Pseudophakia | 6 | 2024 | 12 | 1.590 |
Why?
| Male | 64 | 2025 | 25907 | 1.590 |
Why?
| Angiogenesis Inhibitors | 7 | 2022 | 183 | 1.450 |
Why?
| Fluorocarbons | 3 | 2023 | 58 | 1.450 |
Why?
| Fibrin | 2 | 2023 | 10 | 1.420 |
Why?
| Female | 61 | 2025 | 27081 | 1.420 |
Why?
| Databases, Factual | 11 | 2024 | 673 | 1.410 |
Why?
| Intravitreal Injections | 15 | 2023 | 33 | 1.400 |
Why?
| Paracentesis | 2 | 2023 | 13 | 1.400 |
Why?
| Sclera | 2 | 2024 | 5 | 1.360 |
Why?
| Tissue Plasminogen Activator | 2 | 2023 | 110 | 1.310 |
Why?
| Macular Degeneration | 4 | 2024 | 27 | 1.280 |
Why?
| Lenses, Intraocular | 2 | 2022 | 7 | 1.260 |
Why?
| Follow-Up Studies | 15 | 2024 | 2242 | 1.240 |
Why?
| Retinal Perforations | 4 | 2023 | 8 | 1.190 |
Why?
| Choroid | 5 | 2024 | 14 | 1.170 |
Why?
| Retina | 7 | 2024 | 63 | 1.150 |
Why?
| Fractals | 2 | 2024 | 8 | 1.150 |
Why?
| Internet | 3 | 2024 | 259 | 1.130 |
Why?
| Iris Diseases | 3 | 2020 | 4 | 1.120 |
Why?
| Adult | 32 | 2024 | 13577 | 1.120 |
Why?
| Wet Macular Degeneration | 3 | 2022 | 6 | 1.120 |
Why?
| Candidiasis | 3 | 2021 | 111 | 1.080 |
Why?
| Eye Injuries | 4 | 2024 | 25 | 1.040 |
Why?
| Societies, Medical | 3 | 2019 | 187 | 1.030 |
Why?
| Antihypertensive Agents | 3 | 2024 | 125 | 1.010 |
Why?
| Muscarinic Agonists | 1 | 2024 | 11 | 0.950 |
Why?
| Pilocarpine | 1 | 2024 | 25 | 0.940 |
Why?
| Retinitis | 2 | 2022 | 5 | 0.940 |
Why?
| Lens Subluxation | 1 | 2024 | 2 | 0.930 |
Why?
| Endotamponade | 4 | 2018 | 8 | 0.920 |
Why?
| Limbus Corneae | 1 | 2024 | 8 | 0.920 |
Why?
| Lighting | 1 | 2024 | 5 | 0.900 |
Why?
| Ciliary Body | 1 | 2024 | 3 | 0.900 |
Why?
| Anterior Chamber | 1 | 2023 | 5 | 0.890 |
Why?
| Lens, Crystalline | 1 | 2024 | 19 | 0.880 |
Why?
| Laser Coagulation | 1 | 2024 | 26 | 0.880 |
Why?
| Triamcinolone Acetonide | 5 | 2011 | 15 | 0.870 |
Why?
| Ocular Hypertension | 2 | 2016 | 7 | 0.870 |
Why?
| Panuveitis | 2 | 2021 | 6 | 0.870 |
Why?
| Anesthesia, General | 3 | 2024 | 99 | 0.860 |
Why?
| Germination | 1 | 2023 | 5 | 0.840 |
Why?
| Endoscopy | 1 | 2024 | 119 | 0.840 |
Why?
| Occlusive Dressings | 1 | 2022 | 6 | 0.820 |
Why?
| Cocaine-Related Disorders | 1 | 2025 | 209 | 0.810 |
Why?
| Incidence | 13 | 2024 | 1032 | 0.810 |
Why?
| State Medicine | 5 | 2023 | 14 | 0.810 |
Why?
| HIV Seropositivity | 1 | 2022 | 26 | 0.800 |
Why?
| Rift Valley Fever | 1 | 2022 | 1 | 0.800 |
Why?
| Reproducibility of Results | 8 | 2024 | 1197 | 0.790 |
Why?
| Artificial Intelligence | 1 | 2023 | 96 | 0.790 |
Why?
| Optic Neuropathy, Ischemic | 1 | 2022 | 8 | 0.790 |
Why?
| Eye Foreign Bodies | 1 | 2022 | 6 | 0.780 |
Why?
| Patient Education as Topic | 5 | 2024 | 320 | 0.780 |
Why?
| Enbucrilate | 1 | 2021 | 6 | 0.780 |
Why?
| Tissue Adhesives | 1 | 2021 | 13 | 0.770 |
Why?
| Vitreous Detachment | 2 | 2025 | 2 | 0.760 |
Why?
| Stress, Physiological | 2 | 2019 | 171 | 0.750 |
Why?
| Risk Factors | 12 | 2025 | 3724 | 0.740 |
Why?
| Varicose Veins | 2 | 2019 | 19 | 0.740 |
Why?
| Child | 17 | 2024 | 6906 | 0.740 |
Why?
| Droughts | 4 | 2023 | 9 | 0.730 |
Why?
| Candida | 4 | 2020 | 59 | 0.720 |
Why?
| Choroiditis | 1 | 2020 | 9 | 0.720 |
Why?
| Treatment Outcome | 15 | 2024 | 5283 | 0.710 |
Why?
| Retinal Vein | 2 | 2019 | 3 | 0.680 |
Why?
| Photography | 4 | 2013 | 30 | 0.670 |
Why?
| Eyeglasses | 1 | 2019 | 9 | 0.660 |
Why?
| Surgical Instruments | 1 | 2019 | 27 | 0.660 |
Why?
| Crohn Disease | 1 | 2020 | 93 | 0.660 |
Why?
| Trichoderma | 1 | 2019 | 1 | 0.660 |
Why?
| Plant Diseases | 1 | 2019 | 7 | 0.650 |
Why?
| Suture Techniques | 2 | 2022 | 57 | 0.640 |
Why?
| Vitreous Body | 6 | 2025 | 20 | 0.630 |
Why?
| Laser Therapy | 1 | 2019 | 83 | 0.620 |
Why?
| Fovea Centralis | 1 | 2018 | 5 | 0.620 |
Why?
| Basement Membrane | 1 | 2018 | 16 | 0.620 |
Why?
| Imaging, Three-Dimensional | 1 | 2019 | 150 | 0.610 |
Why?
| HIV Infections | 1 | 2022 | 352 | 0.610 |
Why?
| Vascular Endothelial Growth Factor A | 5 | 2022 | 182 | 0.600 |
Why?
| National Health Programs | 2 | 2015 | 18 | 0.600 |
Why?
| Fluocinolone Acetonide | 1 | 2017 | 5 | 0.580 |
Why?
| Egypt | 4 | 2022 | 13 | 0.580 |
Why?
| Vision Disorders | 5 | 2024 | 59 | 0.580 |
Why?
| Ophthalmic Solutions | 3 | 2024 | 19 | 0.580 |
Why?
| Air | 2 | 2016 | 22 | 0.560 |
Why?
| Prospective Studies | 8 | 2024 | 2378 | 0.550 |
Why?
| Minerals | 1 | 2016 | 29 | 0.530 |
Why?
| Sodium Chloride | 1 | 2016 | 55 | 0.520 |
Why?
| Chorioretinitis | 3 | 2024 | 9 | 0.520 |
Why?
| Acetates | 1 | 2016 | 49 | 0.520 |
Why?
| Dissection | 1 | 2016 | 14 | 0.520 |
Why?
| Ophthalmologic Surgical Procedures | 1 | 2016 | 22 | 0.510 |
Why?
| Cross-Sectional Studies | 7 | 2024 | 1610 | 0.500 |
Why?
| Anesthesia, Local | 1 | 2015 | 16 | 0.490 |
Why?
| Registries | 2 | 2018 | 563 | 0.490 |
Why?
| Adrenergic alpha-1 Receptor Antagonists | 2 | 2020 | 8 | 0.490 |
Why?
| Child, Preschool | 10 | 2024 | 3942 | 0.480 |
Why?
| Microvessels | 2 | 2024 | 30 | 0.450 |
Why?
| Consumer Health Information | 2 | 2024 | 18 | 0.450 |
Why?
| Device Removal | 1 | 2014 | 85 | 0.430 |
Why?
| Treponema pallidum | 3 | 2024 | 10 | 0.420 |
Why?
| Macula Lutea | 2 | 2025 | 5 | 0.410 |
Why?
| Iris | 3 | 2022 | 6 | 0.410 |
Why?
| Scleral Buckling | 3 | 2023 | 5 | 0.380 |
Why?
| Physical Examination | 2 | 2013 | 93 | 0.380 |
Why?
| Optic Disk | 2 | 2021 | 21 | 0.380 |
Why?
| Electronic Health Records | 4 | 2024 | 220 | 0.380 |
Why?
| Mydriatics | 1 | 2011 | 12 | 0.370 |
Why?
| Microscopy | 1 | 2011 | 59 | 0.360 |
Why?
| United States | 9 | 2024 | 4955 | 0.360 |
Why?
| Seasons | 2 | 2022 | 79 | 0.350 |
Why?
| Diagnostic Techniques, Ophthalmological | 2 | 2023 | 11 | 0.330 |
Why?
| Genotype | 2 | 2023 | 533 | 0.330 |
Why?
| Anti-Bacterial Agents | 5 | 2024 | 745 | 0.330 |
Why?
| Fibrinolytic Agents | 2 | 2023 | 125 | 0.330 |
Why?
| Intraoperative Period | 2 | 2019 | 45 | 0.320 |
Why?
| Vision, Low | 2 | 2022 | 9 | 0.320 |
Why?
| Fundus Oculi | 3 | 2024 | 25 | 0.320 |
Why?
| Lens Capsule, Crystalline | 2 | 2016 | 2 | 0.320 |
Why?
| Tonometry, Ocular | 2 | 2024 | 5 | 0.310 |
Why?
| Adrenergic alpha-Antagonists | 1 | 2008 | 27 | 0.300 |
Why?
| Silicone Oils | 3 | 2023 | 3 | 0.300 |
Why?
| Eye Infections, Viral | 1 | 2008 | 3 | 0.300 |
Why?
| Ocular Hypotension | 1 | 2008 | 2 | 0.300 |
Why?
| Eye Infections, Parasitic | 1 | 2008 | 2 | 0.300 |
Why?
| Choroid Neoplasms | 1 | 2007 | 6 | 0.290 |
Why?
| Suction | 1 | 2008 | 23 | 0.290 |
Why?
| Teaching Materials | 2 | 2024 | 32 | 0.290 |
Why?
| Phenotype | 2 | 2022 | 739 | 0.290 |
Why?
| Physicians, Family | 1 | 2008 | 64 | 0.290 |
Why?
| Eye Burns | 1 | 2007 | 1 | 0.280 |
Why?
| Sulfonamides | 1 | 2008 | 126 | 0.280 |
Why?
| Hyaluronic Acid | 1 | 2007 | 34 | 0.280 |
Why?
| Anti-Infective Agents | 1 | 2008 | 95 | 0.270 |
Why?
| Adolescent | 9 | 2024 | 6443 | 0.270 |
Why?
| Vaccination | 3 | 2024 | 280 | 0.260 |
Why?
| Young Adult | 8 | 2024 | 4102 | 0.250 |
Why?
| Prostaglandins, Synthetic | 1 | 2024 | 1 | 0.240 |
Why?
| Dry Eye Syndromes | 1 | 2024 | 10 | 0.240 |
Why?
| Administration, Topical | 1 | 2024 | 57 | 0.240 |
Why?
| Trabeculectomy | 1 | 2024 | 9 | 0.240 |
Why?
| Glaucoma Drainage Implants | 1 | 2024 | 6 | 0.230 |
Why?
| Cohort Studies | 2 | 2022 | 1452 | 0.230 |
Why?
| Vitreoretinopathy, Proliferative | 1 | 2024 | 3 | 0.230 |
Why?
| Syphilis Serodiagnosis | 1 | 2024 | 4 | 0.230 |
Why?
| Melanoma | 1 | 2007 | 280 | 0.230 |
Why?
| Garlic | 1 | 2024 | 5 | 0.230 |
Why?
| Proanthocyanidins | 1 | 2024 | 3 | 0.230 |
Why?
| Abducens Nerve Diseases | 1 | 2024 | 7 | 0.230 |
Why?
| Ciliary Arteries | 1 | 2024 | 3 | 0.230 |
Why?
| Burns, Chemical | 1 | 2024 | 9 | 0.230 |
Why?
| Health Knowledge, Attitudes, Practice | 1 | 2008 | 491 | 0.220 |
Why?
| Propensity Score | 1 | 2024 | 136 | 0.220 |
Why?
| Search Engine | 1 | 2023 | 8 | 0.220 |
Why?
| Pseudotumor Cerebri | 1 | 2024 | 26 | 0.220 |
Why?
| Glaucoma, Open-Angle | 1 | 2024 | 23 | 0.220 |
Why?
| Inflammation | 3 | 2022 | 610 | 0.220 |
Why?
| Tattooing | 1 | 2023 | 5 | 0.220 |
Why?
| Geographic Atrophy | 1 | 2023 | 2 | 0.220 |
Why?
| Sex Workers | 1 | 2023 | 2 | 0.220 |
Why?
| Cultural Diversity | 1 | 2023 | 37 | 0.210 |
Why?
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2024 | 121 | 0.210 |
Why?
| Drainage | 1 | 2023 | 79 | 0.210 |
Why?
| Fibrinolysin | 1 | 2023 | 2 | 0.210 |
Why?
| Odds Ratio | 1 | 2025 | 551 | 0.210 |
Why?
| Self Report | 1 | 2024 | 206 | 0.210 |
Why?
| Retreatment | 2 | 2014 | 56 | 0.210 |
Why?
| Schools, Medical | 1 | 2023 | 70 | 0.210 |
Why?
| ROC Curve | 1 | 2023 | 226 | 0.210 |
Why?
| Patient Selection | 1 | 2024 | 259 | 0.210 |
Why?
| Dementia | 1 | 2024 | 148 | 0.210 |
Why?
| Faculty, Medical | 1 | 2023 | 92 | 0.200 |
Why?
| Vision Screening | 1 | 2022 | 10 | 0.200 |
Why?
| Blood-Retinal Barrier | 1 | 2022 | 5 | 0.200 |
Why?
| Subretinal Fluid | 1 | 2022 | 2 | 0.200 |
Why?
| Feasibility Studies | 1 | 2024 | 390 | 0.200 |
Why?
| Disease Management | 2 | 2021 | 178 | 0.200 |
Why?
| Sudan | 1 | 2022 | 2 | 0.200 |
Why?
| Privacy | 1 | 2022 | 16 | 0.200 |
Why?
| Health Literacy | 4 | 2024 | 129 | 0.200 |
Why?
| Antibodies, Monoclonal, Humanized | 2 | 2015 | 226 | 0.200 |
Why?
| Cyanoacrylates | 1 | 2021 | 6 | 0.200 |
Why?
| Fibrin Tissue Adhesive | 1 | 2021 | 12 | 0.190 |
Why?
| Recombinant Fusion Proteins | 1 | 2022 | 179 | 0.190 |
Why?
| Prednisone | 1 | 2022 | 101 | 0.190 |
Why?
| Eye Abnormalities | 1 | 2021 | 24 | 0.190 |
Why?
| Vision, Ocular | 1 | 2021 | 9 | 0.190 |
Why?
| Eye | 1 | 2021 | 24 | 0.190 |
Why?
| Infant | 5 | 2024 | 3628 | 0.190 |
Why?
| Ecosystem | 1 | 2022 | 65 | 0.190 |
Why?
| Diabetes Mellitus, Type 1 | 1 | 2024 | 199 | 0.190 |
Why?
| Prevalence | 3 | 2022 | 971 | 0.190 |
Why?
| Sensitivity and Specificity | 1 | 2023 | 859 | 0.190 |
Why?
| Genome-Wide Association Study | 1 | 2022 | 163 | 0.180 |
Why?
| Disease Outbreaks | 1 | 2022 | 120 | 0.180 |
Why?
| Tomography, X-Ray Computed | 2 | 2022 | 1164 | 0.180 |
Why?
| Prolapse | 1 | 2020 | 6 | 0.180 |
Why?
| Randomized Controlled Trials as Topic | 1 | 2024 | 573 | 0.180 |
Why?
| Fungemia | 1 | 2021 | 37 | 0.180 |
Why?
| Oximetry | 2 | 2011 | 68 | 0.170 |
Why?
| Ophthalmoscopy | 1 | 2020 | 14 | 0.170 |
Why?
| Swine | 1 | 2021 | 408 | 0.170 |
Why?
| Bacteria | 1 | 2022 | 218 | 0.170 |
Why?
| Carcinoma, Hepatocellular | 1 | 2022 | 195 | 0.170 |
Why?
| Retinal Pigment Epithelium | 1 | 2020 | 11 | 0.170 |
Why?
| Blindness | 2 | 2022 | 31 | 0.170 |
Why?
| Algorithms | 1 | 2023 | 625 | 0.170 |
Why?
| Substance Abuse, Intravenous | 1 | 2020 | 43 | 0.170 |
Why?
| Polymorphism, Single Nucleotide | 1 | 2022 | 475 | 0.160 |
Why?
| Fusariosis | 1 | 2019 | 6 | 0.160 |
Why?
| Plant Roots | 1 | 2019 | 33 | 0.160 |
Why?
| Fusarium | 1 | 2019 | 31 | 0.160 |
Why?
| Quantitative Trait Loci | 1 | 2019 | 42 | 0.160 |
Why?
| Hepatitis C | 1 | 2020 | 80 | 0.160 |
Why?
| Referral and Consultation | 3 | 2013 | 288 | 0.160 |
Why?
| Liver Neoplasms | 1 | 2022 | 326 | 0.160 |
Why?
| MicroRNAs | 1 | 2022 | 344 | 0.160 |
Why?
| Emergencies | 2 | 2009 | 79 | 0.160 |
Why?
| Animals | 3 | 2024 | 13124 | 0.160 |
Why?
| Chromosome Mapping | 1 | 2019 | 153 | 0.150 |
Why?
| Water | 1 | 2019 | 76 | 0.150 |
Why?
| Antibiotic Prophylaxis | 1 | 2019 | 62 | 0.150 |
Why?
| Equipment Design | 1 | 2019 | 289 | 0.150 |
Why?
| Gaucher Disease | 1 | 2018 | 14 | 0.150 |
Why?
| Alleles | 1 | 2019 | 256 | 0.150 |
Why?
| Recurrence | 2 | 2011 | 659 | 0.150 |
Why?
| Surgical Wound Infection | 1 | 2019 | 115 | 0.150 |
Why?
| Sulfur Hexafluoride | 1 | 2017 | 2 | 0.150 |
Why?
| Treatment Failure | 1 | 2018 | 118 | 0.140 |
Why?
| Drug Therapy, Combination | 2 | 2016 | 384 | 0.140 |
Why?
| Diabetes Mellitus, Type 2 | 1 | 2024 | 519 | 0.140 |
Why?
| Eye Diseases, Hereditary | 1 | 2017 | 5 | 0.140 |
Why?
| Fatty Acids | 1 | 2018 | 144 | 0.140 |
Why?
| Inheritance Patterns | 1 | 2017 | 22 | 0.140 |
Why?
| Penicillins | 1 | 2017 | 29 | 0.140 |
Why?
| Carbonic Anhydrase Inhibitors | 2 | 2024 | 6 | 0.140 |
Why?
| Contrast Media | 1 | 2018 | 192 | 0.140 |
Why?
| Time Factors | 3 | 2020 | 2935 | 0.130 |
Why?
| Microsurgery | 2 | 2024 | 30 | 0.130 |
Why?
| Drug Combinations | 1 | 2016 | 127 | 0.130 |
Why?
| Video Recording | 1 | 2016 | 79 | 0.130 |
Why?
| Anesthetics, General | 1 | 2015 | 4 | 0.120 |
Why?
| Visually Impaired Persons | 1 | 2015 | 1 | 0.120 |
Why?
| Dose-Response Relationship, Drug | 2 | 2016 | 1372 | 0.120 |
Why?
| England | 2 | 2012 | 45 | 0.120 |
Why?
| Anesthetics, Local | 1 | 2015 | 76 | 0.120 |
Why?
| Acute Disease | 2 | 2021 | 373 | 0.120 |
Why?
| Microscopy, Acoustic | 1 | 2013 | 5 | 0.110 |
Why?
| Reading | 2 | 2024 | 85 | 0.110 |
Why?
| Language | 2 | 2024 | 138 | 0.110 |
Why?
| Diagnosis, Differential | 3 | 2017 | 1033 | 0.110 |
Why?
| Glaucoma, Neovascular | 1 | 2012 | 2 | 0.100 |
Why?
| Infusions, Intravenous | 2 | 2017 | 213 | 0.100 |
Why?
| Syndrome | 2 | 2011 | 240 | 0.090 |
Why?
| Risk Assessment | 1 | 2016 | 1270 | 0.090 |
Why?
| Mutation | 1 | 2017 | 1280 | 0.090 |
Why?
| Muscle Hypotonia | 1 | 2011 | 21 | 0.090 |
Why?
| Risperidone | 1 | 2011 | 25 | 0.090 |
Why?
| Eye Hemorrhage | 1 | 2010 | 1 | 0.090 |
Why?
| Cranial Sinuses | 1 | 2010 | 10 | 0.090 |
Why?
| Carotid Artery Injuries | 1 | 2010 | 13 | 0.090 |
Why?
| Arteriovenous Fistula | 1 | 2010 | 30 | 0.080 |
Why?
| Anti-Inflammatory Agents | 1 | 2011 | 163 | 0.080 |
Why?
| Prostaglandins F, Synthetic | 1 | 2009 | 1 | 0.080 |
Why?
| Prednisolone | 1 | 2009 | 53 | 0.080 |
Why?
| Antipsychotic Agents | 1 | 2011 | 233 | 0.080 |
Why?
| Acetazolamide | 1 | 2008 | 19 | 0.080 |
Why?
| Oxygen | 1 | 2011 | 321 | 0.080 |
Why?
| Pupil | 1 | 2008 | 29 | 0.080 |
Why?
| Mass Screening | 1 | 2011 | 344 | 0.070 |
Why?
| Vitreous Hemorrhage | 1 | 2008 | 4 | 0.070 |
Why?
| Prostatic Hyperplasia | 1 | 2008 | 39 | 0.070 |
Why?
| Injections | 1 | 2008 | 57 | 0.070 |
Why?
| Models, Biological | 1 | 2011 | 716 | 0.070 |
Why?
| Electroretinography | 2 | 2018 | 17 | 0.070 |
Why?
| Cefuroxime | 1 | 2007 | 3 | 0.070 |
Why?
| Cefazolin | 1 | 2007 | 9 | 0.070 |
Why?
| Capsulorhexis | 1 | 2007 | 1 | 0.070 |
Why?
| Rupture | 1 | 2007 | 24 | 0.070 |
Why?
| Astigmatism | 1 | 2007 | 5 | 0.070 |
Why?
| Neoplasm Metastasis | 1 | 2007 | 232 | 0.070 |
Why?
| Chronic Disease | 1 | 2009 | 573 | 0.070 |
Why?
| Clinical Competence | 1 | 2008 | 398 | 0.060 |
Why?
| Tissue Adhesions | 1 | 2025 | 35 | 0.060 |
Why?
| Reagins | 1 | 2024 | 2 | 0.060 |
Why?
| Posterior Eye Segment | 1 | 2024 | 2 | 0.060 |
Why?
| Sex Distribution | 1 | 2024 | 136 | 0.060 |
Why?
| Prosthesis Implantation | 1 | 2024 | 47 | 0.060 |
Why?
| Antibodies, Bacterial | 1 | 2024 | 27 | 0.060 |
Why?
| Rumen | 1 | 2024 | 1 | 0.060 |
Why?
| Tannins | 1 | 2024 | 3 | 0.060 |
Why?
| Fermentation | 1 | 2024 | 9 | 0.060 |
Why?
| Goats | 1 | 2024 | 11 | 0.060 |
Why?
| Diplopia | 1 | 2024 | 19 | 0.060 |
Why?
| Animal Feed | 1 | 2024 | 56 | 0.060 |
Why?
| Antifungal Agents | 1 | 2006 | 331 | 0.050 |
Why?
| Immunoglobulin G | 1 | 2024 | 190 | 0.050 |
Why?
| Anesthesia | 1 | 2024 | 73 | 0.050 |
Why?
| Surgical Flaps | 1 | 2024 | 114 | 0.050 |
Why?
| Homosexuality, Male | 1 | 2023 | 51 | 0.050 |
Why?
| Retinal Ganglion Cells | 1 | 2022 | 14 | 0.050 |
Why?
| Traction | 1 | 2021 | 7 | 0.050 |
Why?
| Reoperation | 2 | 2014 | 460 | 0.050 |
Why?
| Socioeconomic Factors | 1 | 2023 | 591 | 0.040 |
Why?
| Health Status Disparities | 1 | 2023 | 202 | 0.040 |
Why?
| Atrophy | 1 | 2020 | 37 | 0.040 |
Why?
| Emergency Service, Hospital | 1 | 2024 | 484 | 0.040 |
Why?
| Diet | 1 | 2024 | 568 | 0.040 |
Why?
| Healthcare Disparities | 1 | 2023 | 281 | 0.040 |
Why?
| Pandemics | 1 | 2024 | 563 | 0.040 |
Why?
| Europe | 1 | 2019 | 79 | 0.040 |
Why?
| Gene Expression Regulation, Neoplastic | 1 | 2022 | 833 | 0.040 |
Why?
| Administration, Oral | 2 | 2011 | 434 | 0.040 |
Why?
| Glucosylceramidase | 1 | 2018 | 9 | 0.040 |
Why?
| Enzyme Replacement Therapy | 1 | 2018 | 17 | 0.040 |
Why?
| Visual Fields | 1 | 2018 | 39 | 0.040 |
Why?
| Transplantation, Autologous | 1 | 2020 | 481 | 0.040 |
Why?
| Prone Position | 1 | 2017 | 31 | 0.040 |
Why?
| Genes, Recessive | 1 | 2017 | 15 | 0.040 |
Why?
| Consanguinity | 1 | 2017 | 17 | 0.040 |
Why?
| Heterozygote | 1 | 2017 | 83 | 0.030 |
Why?
| Pedigree | 1 | 2017 | 119 | 0.030 |
Why?
| Recombinant Proteins | 1 | 2018 | 476 | 0.030 |
Why?
| DNA Mutational Analysis | 1 | 2017 | 175 | 0.030 |
Why?
| Genetic Association Studies | 1 | 2017 | 119 | 0.030 |
Why?
| Genetic Testing | 1 | 2017 | 120 | 0.030 |
Why?
| Rupture, Spontaneous | 1 | 2016 | 19 | 0.030 |
Why?
| Pregnancy | 1 | 2023 | 2452 | 0.030 |
Why?
| Practice Guidelines as Topic | 1 | 2019 | 468 | 0.030 |
Why?
| Survival Analysis | 1 | 2016 | 661 | 0.030 |
Why?
| Choroidal Neovascularization | 1 | 2013 | 19 | 0.030 |
Why?
| Gonioscopy | 1 | 2012 | 3 | 0.030 |
Why?
| Age Distribution | 1 | 2013 | 170 | 0.030 |
Why?
| Neovascularization, Pathologic | 1 | 2012 | 155 | 0.020 |
Why?
| Retinal Artery | 1 | 2011 | 5 | 0.020 |
Why?
| Coloring Agents | 1 | 2011 | 66 | 0.020 |
Why?
| Serotonin 5-HT2 Receptor Antagonists | 1 | 2011 | 9 | 0.020 |
Why?
| Indocyanine Green | 1 | 2011 | 34 | 0.020 |
Why?
| Dopamine Antagonists | 1 | 2011 | 22 | 0.020 |
Why?
| Angiography | 1 | 2011 | 128 | 0.020 |
Why?
| Injections, Intraocular | 1 | 2010 | 2 | 0.020 |
Why?
| Regional Blood Flow | 1 | 2011 | 109 | 0.020 |
Why?
| Methylprednisolone | 1 | 2010 | 39 | 0.020 |
Why?
| Orbit | 1 | 2010 | 27 | 0.020 |
Why?
| Chemotherapy, Adjuvant | 1 | 2011 | 121 | 0.020 |
Why?
| Adrenal Cortex Hormones | 1 | 2011 | 99 | 0.020 |
Why?
| Schizophrenia | 1 | 2011 | 258 | 0.020 |
Why?
| Immunosuppressive Agents | 1 | 2011 | 225 | 0.020 |
Why?
| Sweden | 1 | 2007 | 10 | 0.020 |
Why?
|
|
Sallam's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|